Autologous anti-mesothelin CAR-IL-7-CCL19-expressing T lymphocytes TAK-103

{
  "id": "MLC-T-ONC-011472",
  "term": "Autologous anti-mesothelin CAR-IL-7-CCL19-expressing T lymphocytes TAK-103",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin (MSLN) and simultaneously produce interleukin-7 (IL-7) and C-C motif chemokine 19 (CCL19), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-MSLN CAR-T cells TAK-103 specifically target and kill MSLN-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. IL-7 promotes the proliferation and survival of T cells. CCL19 enhances the migration of T cells and dendritic cells (DCs).",
  "synonyms": [
    "autologous anti-mesothelin CAR T Cells TAK-103",
    "autologous anti-MSLN CAR T cells TAK-103",
    "CAR T cells TAK-103"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-mesothelin-car-il-7-ccl19-expressing-t-lymphocytes-tak-103/"
}